Table 3.

ABRs of 7-, 10-, and 14-d prophylaxis regimens

	Prophylaxis (group 1) across-treatment regimens			Prophylaxis (group 1)* within-subject comparison
	7-d Regimen (N = 40)	10-d Regimen (N = 7)	14-d Regimen (N = 21)	7-d Regimen (N = 21)	14-d Regimen (N = 21)	7-d vs 14-d Regimen
AsBR
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 1.0)	0 (0, 0)	0 (0, 1.0)
Estimated rate†	0.65	0.56	0.83	0.29	0.83	0.35
95% CI†	0.37, 1.13	0.27, 1.17	0.38, 1.77	0.068, 1.198	0.385, 1.771	0.076, 1.575
Mean difference (95% CI)‡						−0.79 (−1.780, 0.197)
Total ABR
Median (IQR)	0 (0, 1.87)	0 (0, 1.78)	1.08 (0, 2.7)	0 (0, 1.53)	1.08 (0, 2.70)
Estimated rate†	1.58	1.69	1.61	0.69	1.61	0.43
95% CI†	1.02, 2.44	0.87, 3.28	0.93, 2.80	0.296, 1.626	0.930, 2.801	0.162, 1.138
Mean difference (95% CI)‡						−1.25 (−2.562, 0.070)
Joint ABR
Median (IQR)	0 (0, 1.53)	0 (0, 0.88)	0 (0, 1.04)	0 (0, 0)	0 (0, 1.04)
Estimated rate†	1.13	0.92	1.11	0.41	1.11	0.36
95% CI†	0.70, 1.84	0.41, 2.04	0.51, 2.41	0.141, 1.161	0.513, 2.414	0.111, 1.199
Mean difference (95% CI)‡						−0.97 (−2.197, 0.249)
Treatment duration, wk
Median (IQR)	38.4 (30.0, 82.3)	34.3 (21.3, 58.6)	55.1 (37.0, 63.6)

The median assigned doses for the 7-, 10-, and 14-d prophylaxis regimens were 40, 75, and 75 IU/kg, respectively.

^*Includes subjects with a minimum of 12 wk of treatment on both 7-d and 14-d prophylaxis.

^†The estimated rate was calculated assuming a Poisson distribution.

^‡95% CI based on Student t test from matched pairs design.